Ampligen in Chronic Fatigue Syndrome

Autoimmunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

NCT03254823 ·Status: COMPLETED

Clinical Study of Cizutamig in Systemic Lupus Erythematosus

NCT07215663 ·Status: RECRUITING ·Phase: PHASE1

A Study of Imvotamab in Severe Systemic Lupus Erythematosus

NCT06041568 ·Status: TERMINATED ·Phase: PHASE1

Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

NCT03613129 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE

NCT01702038 ·Status: WITHDRAWN ·Phase: PHASE2

Immune Ablation and Hematopoietic Stem Cell Support in Patients With Systemic Lupus Erythematosus: A Phase II Study

NCT00271934 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease

NCT06497387 ·Status: RECRUITING ·Phase: EARLY_PHASE1

Autologous Stem Cell Transplantation: International Lupus Trial

NCT05063513 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3

A Study of AMG 557 in Adults With Systemic Lupus Erythematosus

NCT00774943 ·Status: COMPLETED ·Phase: PHASE1

An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis

NCT01273389 ·Status: COMPLETED ·Phase: PHASE2

Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE

NCT07031713 ·Status: RECRUITING ·Phase: PHASE1

Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus

NCT00556192 ·Status: COMPLETED ·Phase: PHASE2

Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)

NCT01261793 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

NCT02550652 ·Status: COMPLETED ·Phase: PHASE2

Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus.

NCT02891213 ·Status: UNKNOWN

A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus

NCT05866861 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Safety Study of CC312 in Autoimmune Disease Patients

NCT06888960 ·Status: RECRUITING ·Phase: EARLY_PHASE1

B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome

NCT01156922 ·Status: TERMINATED ·Phase: PHASE2

Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus

NCT00017641 ·Status: UNKNOWN ·Phase: PHASE1

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus

NCT02391259 ·Status: COMPLETED ·Phase: PHASE1

An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults

NCT01753193 ·Status: COMPLETED ·Phase: PHASE2

Safety Study of AMG 557 in Subjects With Lupus Arthritis

NCT01683695 ·Status: COMPLETED ·Phase: PHASE1

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus

NCT02535689 ·Status: COMPLETED ·Phase: PHASE1

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

NCT04961567 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)

NCT02955615 ·Status: COMPLETED ·Phase: PHASE2